Sutter Bay Hospitals
Sutter Bay Hospitals was paid $29.48M by Medicaid between Mar 2018 and Dec 2024, across 222 billing codes. Its largest line is 0450, Emergency room services — 22% of everything it billed.
ANTIOCH, CA 94509
Next to other General Acute Care Hospital providers in California
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 101,920 | $2.87M | |
| 2019 | 123,967 | $3.54M | |
| 2020 | 88,961 | $2.61M | |
| 2021 | 106,212 | $3.60M | |
| 2022 | 136,606 | $5.11M | |
| 2023 | 170,822 | $5.77M | |
| 2024incomplete | 184,864 | $5.98M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 22% | 121,640 | 108,234 | $6.49M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 5.5% | 7,930 | 7,633 | $1.63M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 5.4% | 7,579 | 7,430 | $1.59M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 4,571 | 4,462 | $1.32M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.4% | 15,735 | 14,631 | $1.31M |
| J3490 | Unclassified drugs | 3.8% | 98,067 | 50,440 | $1.12M |
| 99199 | Unlisted special service, procedure or report | 3.5% | 7,655 | 6,541 | $1.03M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.0% | 29,922 | 27,076 | $872K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.7% | 12,888 | 11,321 | $810K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 6,001 | 5,785 | $708K |
| 80053 | Comprehensive metabolic panel | 1.9% | 51,555 | 46,459 | $562K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 7,605 | 7,375 | $530K |
210 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 4,887 | $529K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 12,725 | $471K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 57,704 | $448K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 5,332 | $432K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 1,488 | $390K |
| Z7502 | 1.3% | 9,876 | $369K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 2,354 | $342K |
| 99284 | Emergency room visit (serious) | 1.1% | 6,119 | $317K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 11,679 | $309K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,229 | $286K |
| 84484 | <1% | 26,486 | $272K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,688 | $234K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,389 | $218K |
| 36430 | <1% | 3,514 | $217K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,551 | $216K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,550 | $214K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,098 | $199K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,331 | $197K |
| 76801 | <1% | 2,195 | $190K | |
| 93971 | <1% | 1,469 | $176K | |
| 82077 | <1% | 2,971 | $171K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,582 | $168K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,818 | $151K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 597 | $149K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,528 | $148K |
| 83880 | <1% | 4,342 | $145K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13,840 | $145K |
| 83690 | <1% | 19,492 | $142K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,865 | $134K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,588 | $128K |
| 99283 | Emergency room visit (moderate) | <1% | 2,959 | $126K |
| 99285 | Emergency room visit (most serious) | <1% | 1,540 | $121K |
| 70496 | <1% | 443 | $119K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,027 | $118K |
| 70498 | <1% | 428 | $115K | |
| 0762 | <1% | 1,038 | $106K | |
| 90715 | <1% | 1,720 | $98K | |
| 83735 | <1% | 13,579 | $95K | |
| 87040 | <1% | 6,528 | $87K | |
| 80143 | <1% | 1,418 | $87K | |
| 83605 | <1% | 8,033 | $86K | |
| 84703 | <1% | 11,505 | $81K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,176 | $79K |
| 80179 | <1% | 1,348 | $78K | |
| 0510 | <1% | 2,109 | $77K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,014 | $76K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 3,881 | $74K |
| 73562 | <1% | 2,511 | $66K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,018 | $65K |
| 73610 | <1% | 2,311 | $64K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,548 | $62K |
| 73630 | <1% | 2,335 | $62K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,559 | $62K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,162 | $60K |
| 84702 | <1% | 3,917 | $57K | |
| 82803 | <1% | 3,903 | $57K | |
| 82947 | <1% | 11,304 | $57K | |
| 81001 | <1% | 16,486 | $56K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 969 | $53K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,492 | $51K |
| 73030 | <1% | 1,839 | $50K | |
| 99070 | <1% | 1,918 | $50K | |
| 96376 | <1% | 2,084 | $49K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,584 | $49K |
| 0272 | <1% | 421 | $44K | |
| 70486 | <1% | 312 | $43K | |
| 73130 | <1% | 1,567 | $43K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,956 | $41K |
| 81025 | <1% | 8,656 | $40K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,525 | $39K |
| 0250 | <1% | 4,305 | $35K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 197 | $34K |
| 93970 | <1% | 165 | $32K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,519 | $32K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 88 | $31K |
| 85379 | <1% | 2,819 | $31K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,422 | $30K |
| 74174 | <1% | 96 | $30K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 295 | $28K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,625 | $27K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,231 | $27K |
| 85610 | <1% | 6,519 | $26K | |
| 73110 | <1% | 925 | $25K | |
| 85730 | <1% | 4,060 | $25K | |
| 87186 | <1% | 2,278 | $24K | |
| 81003 | <1% | 9,539 | $24K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,093 | $23K |
| 72131 | <1% | 168 | $22K | |
| 71250 | <1% | 198 | $22K | |
| 0270 | <1% | 750 | $22K | |
| 87077 | <1% | 2,184 | $21K | |
| 73502 | <1% | 493 | $21K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,113 | $21K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 101 | $20K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,562 | $20K |
| 96367 | <1% | 308 | $19K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 1,233 | $19K |
| Z7610 | <1% | 1,921 | $19K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 88 | $17K |
| 97750 | <1% | 304 | $17K | |
| 76830 | Ultrasound, transvaginal | <1% | 220 | $16K |
| Z9725 | <1% | 334 | $14K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,979 | $13K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,684 | $13K |
| 76770 | <1% | 165 | $13K | |
| 72100 | <1% | 383 | $13K | |
| 73080 | <1% | 444 | $13K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 43 | $12K |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 144 | $12K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,564 | $12K |
| 73140 | <1% | 637 | $12K | |
| 87210 | <1% | 2,433 | $11K | |
| 82550 | <1% | 1,582 | $11K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 418 | $10K |
| 86140 | <1% | 1,680 | $10K | |
| 82805 | <1% | 307 | $9K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 461 | $9K |
| 87400 | <1% | 1,250 | $9K | |
| 86901 | <1% | 2,619 | $9K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 17 | $8K |
| 94644 | <1% | 266 | $8K | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 295 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 782 | $7K |
| 73590 | <1% | 318 | $7K | |
| 84100 | <1% | 1,437 | $7K | |
| 93017 | <1% | 80 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 468 | $6K |
| 86900 | <1% | 1,958 | $6K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 78 | $6K |
| 86850 | <1% | 1,216 | $5K | |
| 76870 | <1% | 109 | $5K | |
| 84439 | <1% | 547 | $5K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 486 | $5K |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 95 | $5K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 208 | $5K |
| 12001 | <1% | 189 | $4K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 639 | $4K |
| 0636 | <1% | 704 | $4K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 58 | $4K |
| 0360 | <1% | 16 | $4K | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 49 | $4K |
| 97139 | <1% | 146 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,185 | $4K |
| 10060 | <1% | 151 | $4K | |
| 74018 | <1% | 158 | $4K | |
| 12011 | <1% | 98 | $3K | |
| 82009 | <1% | 681 | $3K | |
| 84145 | <1% | 83 | $3K | |
| 87420 | <1% | 559 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 319 | $3K |
| 87081 | <1% | 267 | $2K | |
| 87634 | <1% | 25 | $2K | |
| 73090 | <1% | 101 | $2K | |
| 82731 | <1% | 30 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 27 | $2K |
| 29125 | <1% | 200 | $2K | |
| 80061 | Lipid panel | <1% | 91 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 135 | $2K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 183 | $2K |
| 0710 | <1% | 42 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,136 | $2K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 57 | $1K |
| 85652 | <1% | 466 | $1K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 151 | $1K |
| 71101 | <1% | 38 | $1K | |
| 12002 | <1% | 53 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 49 | $1K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 90 | $857.85 |
| 86592 | <1% | 152 | $833.25 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 51 | $794.89 |
| 74019 | <1% | 26 | $786.53 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,428 | $709.64 |
| 82553 | <1% | 54 | $692.97 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 790 | $609.27 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 66 | $554.63 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 34 | $492.30 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 63 | $477.43 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 2,943 | $461.25 |
| 97161 | <1% | 27 | $440.48 | |
| 73564 | <1% | 13 | $410.56 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 78 | $397.71 |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 13 | $388.25 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 164 | $367.40 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 534 | $355.71 |
| 87088 | <1% | 37 | $336.09 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12 | $329.28 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 85 | $306.28 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,256 | $280.93 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 16 | $278.10 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 31 | $245.73 |
| 72170 | <1% | 13 | $237.05 | |
| 86308 | <1% | 42 | $221.79 | |
| 73660 | <1% | 12 | $213.75 | |
| 70360 | <1% | 12 | $207.82 | |
| 87045 | <1% | 14 | $188.39 | |
| 82140 | <1% | 15 | $159.30 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,394 | $150.70 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 17 | $148.24 |
| 87070 | <1% | 17 | $144.60 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 313 | $144.32 |
| 29515 | <1% | 12 | $123.96 | |
| 86701 | <1% | 12 | $104.76 | |
| 87046 | <1% | 26 | $99.54 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 14 | $71.69 |
| 69209 | <1% | 12 | $71.63 | |
| 84132 | <1% | 16 | $66.54 | |
| 87205 | <1% | 16 | $58.02 | |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | <1% | 63 | $9.18 |
| 0250R | 0% | 405 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Sutter Bay Hospitals | Castro Valley, CA | $52.65M |
| Sutter Bay Hospitals | Oakland, CA | $46.80M |
| Sutter Bay Hospitals | Berkeley, CA | $43.78M |
| Sutter Bay Hospitals | Lakeport, CA | $39.50M |
| Sutter Bay Hospitals | Santa Rosa, CA | $35.23M |
| Sutter Bay Hospitals | San Francisco, CA | $19.99M |
| Sutter Bay Hospitals | Burlingame, CA | $17.15M |
| Sutter Bay Hospitals | San Francisco, CA | $14.94M |
| Sutter Bay Hospitals | Novato, CA | $11.12M |
| Sutter Bay Hospitals | San Francisco, CA | $6.79M |
| Sutter Bay Hospitals | Lakeport, CA | $3.99M |
| Sutter East Bay Hospitals | Antioch, CA | $3.45M |
| Sutter Bay Hospitals | Burlingame, CA | $1.98M |
| Sutter Bay Hospitals | Lakeport, CA | $1.72M |
| Sutter East Bay Hospitals | Oakland, CA | $1.10M |
| Sutter Bay Hospitals | San Francisco, CA | $1.08M |
| Sutter East Bay Hospitals | Berkeley, CA | $946K |
| Sutter West Bay Hospitals | San Francisco, CA | $186K |
| Magnetic Imaging Affiliates, LLC | Oakland, CA | $112K |
| Sutter Bay Hospitals | Berkeley, CA | $45K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.